Recommendations for economic evaluations of cell and gene therapies

a systematic literature review with critical appraisal

authored by

Mondher Toumi, Omar Dabbous, Samuel Aballéa, Michael F. Drummond, Johann Matthias Graf von der Schulenburg, Daniel C. Malone, Peter J. Neumann, Sean D. Sullivan, Sean Tunis

Abstract

Objective: No consensus exists on the ideal methodology to evaluate the economic impact and value of new, potentially curative gene therapies. We aimed to identify and describe published methodologic recommendations for the economic evaluation of gene therapies and assess whether these recommendations have been applied in published evaluations. Methods: This study was conducted in three stages: a systematic literature review of methodologic recommendations for economic evaluation of gene therapies; an assessment of the appropriateness of recommendations; and a review to assess the degree to which the recommendations were applied in published evaluations. Results: A total of 2,888 references were screened, 83 articles were reviewed to assess eligibility, and 20 papers were included. Fifty recommendations were identified, and 21 reached consensus thresholds. Most evaluations were based on naive treatment comparisons and did not apply consensus recommendations. Innovative payment mechanisms for gene therapies were rarely considered. The only widely applied recommendations related to modeling choices and methods. Conclusions: Methodological recommendations for economic evaluations of gene therapies are generally not being followed. Assessing the applicability and impact of the recommendations from this study may facilitate the implementation of consensus recommendations in future evaluations.

Organisation(s)

Institute for Risk and Reliability

External Organisation(s)

Universite d'Aix-Marseille
Creativ-Ceutical SA
Univ. York, Dep. Comput. Sci., Non-Stand. Comput. Group
University of Utah
Tufts University
University of Washington
Rubix Health
Novartis Gene Therapies

Type

Review article

Journal

Expert Review of Pharmacoeconomics and Outcomes Research

Volume

23

Pages

483-497

No. of pages

15

ISSN

1473-7167

Publication date

2023

Publication status

Published

Peer reviewed

Yes

ASJC Scopus subject areas

Health Policy, Pharmacology (medical)

Sustainable Development Goals

SDG 3 - Good Health and Well-being

Electronic version(s)

https://doi.org/10.1080/14737167.2023.2197214 (Access: Open)